GluBio
Latest round
- Series A
Last raised
- Aug 2022
Total raised
- $92M
Investors
- 7
About GluBio
, trading as GluBio, operates as a drug developer that focuses on the research and development of molecular gel targeted protein degradation drugs. Gang Lu and Liqiang Fu are the founders of the company. 80% of the employees of the core research team have a doctor's degree. The company established an R & D center located in San Diego, California, USA and Zhangjiang, Shanghai. In February 2026, GluBio closed a strategic investment. The company focuses on the research and development of small molecule protein antidotes. Its products include molecular glue and PROTAC medicine. The company also develops a multidimensional protein degradation screening platform, an innovative target verification platform, a molecular gel rational design platform, and a proprietary high activity molecular library. The company's products can treat recurrent and refractory hematoma. The company generates revenue by doing R&D, and providing molecular glue-targeted protein degradation drugs and other related products.
Who invested in GluBio
7 investors across 3 rounds
See all investors in GluBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GluBio
Who invested in GluBio?
GluBio has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GluBio raised?
GluBio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did GluBio last raise money?
GluBio's most recent round on record is a Series A, in Aug 2022.
What does GluBio do?
, trading as GluBio, operates as a drug developer that focuses on the research and development of molecular gel targeted protein degradation drugs.
Where is GluBio headquartered?
GluBio is headquartered in Shanghai, China.
Which VCs invest in companies like GluBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at GluBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like GluBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.